The effect of graphene oxide on conformation change, aggregation and cytotoxicity of HIV-1 regulatory protein (Vpr)

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1383-1390

  Zhang, Min ^a   Mao, Xiaobo ^a   Wang, Chenxuan ^a,c   Zeng, Wenfeng ^b   Zhang, Chunling ^b   Li, Zhongjun ^a   Fang, Ying ^a   Yang, Yanlian ^a   Liang, Wei ^b   Wang, Chen ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Aggregation; Conformation change; Cytotoxicity; Graphene oxide; Hydrophobic interaction; Vpr13 33

Indexed keywords

CONFORMATION CHANGE; GRAPHENE OXIDES; GRAPHITE SURFACES; HELICAL CONFORMATION; HYDROPHOBIC INTERACTIONS; ION CHANNEL; LARGE UNILAMELLAR VESICLES; MTT ASSAYS; NEUROBLASTOMA CELLS; PORE FORMING; PREFERENTIAL ADSORPTION; REGULATORY PROTEIN; SHEET STRUCTURE; T CELLS; VIRAL PROTEINS; VPR13-33;

ADSORPTION; AGGLOMERATION; AMINO ACIDS; ATOMIC FORCE MICROSCOPY; HYDROPHOBICITY; PROTEINS; SCANNING TUNNELING MICROSCOPY;

CYTOTOXICITY;

GRAPHENE OXIDE; VIRUS PROTEIN;

ADSORPTION; ALPHA HELIX; ANIMAL CELL; ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; CELL VIABILITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CYTOTOXICITY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; SCANNING TUNNELING MICROSCOPY; T LYMPHOCYTE;

CELL SURVIVAL; DIMERIZATION; GRAPHITE; NANOCAPSULES; OXIDES; PROTEIN CONFORMATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870342653     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.067     Document Type: Article

References (52)

1. Lombardo E., Ramírez J.C., Agbandje-McKenna M., Almendral J.M. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. J Virol 2000, 74:3804-3814.
2. Donald J.E., Zhang Y., Fiorin G., Carnevale V., Slochower D.R., Gai F., et al. Transmembrane orientation and possible role of the fusogenic peptide from parainfluenza virus 5 (PIV5) in promoting fusion. Proc Natl Acad Sci U S A 2011, 108:3958-3963.
3. Wolf M., Vo P.T., Greenberg H.B. Rhesus rotavirus entry into a polarized epithelium is endocytosis dependent and involves sequential VP4 conformational changes. J Virol 2011, 85:2492-2503.
4. Bewley C.A., Louis J.M., Ghirlando R., Clore G.M. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002, 277:14238-14245.
5. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001, 70:777-810.
6. White J.M. Viral and cellular membrane fusion proteins. Annu Rev Physiol 1990, 52:675-697.
7. Laura W., Keith W. Physical aspects of viral membrane fusion. The Scientific World J 2009, 9:764-780.
8. Ostuni E., Grzybowski B.A., Mrksich M., Roberts C.S., Whitesides G.M. Adsorption of proteins to hydrophobic sites on mixed self-assembled monolayers. Langmuir 2003, 19:1861-1872.
9. Mao X., Wang Y., Liu L., Niu L., Yang Y., Wang C. Molecular-level evidence of the surface-induced transformation of peptide structures revealed by scanning tunneling microscopy. Langmuir 2009, 25:8849-8853.
10. Sethuraman A., Belfort G. Protein structural perturbation and aggregation on homogeneous surfaces. Biophys J 2005, 88:1322-1333.
11. Horvath C., Lamb R. Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion. J Virol 1992, 66:2443-2455.
12. Piller S.C., Jans P., Gage P.W., Jans D.A. Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc Natl Acad Sci U S A 1998, 95:4595-4600.
13. Mahalingam S., Collman R.G., Patel M., Monken C.E., Srinivasan A. Functional analysis of HIV-1 Vpr: identification of determinants essential for subcellular localization. Virology 1995, 212:331-339.
14. Piller S., Ewart G., Premkumar A., Cox G., Gage P. Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc Natl Acad Sci U S A 1996, 93:111.
15. Romani B., Engelbrecht S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 2009, 90:1795-1805.
16. Piller S.C., Ewart G.D., Jans D.A., Gage P.W., Cox G.B. The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J Virol 1999, 73:4230-4238.
17. Wecker K., Roques B. NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur J Biochem 1999, 266:359-369.
18. Engler A., Stangler T., Willbold D. Solution structure of human immunodeficiency virus type 1 Vpr (13-33) peptide in micelles. Eur J Biochem 2001, 268:389-395.
19. Morellet N., Bouaziz S., Petitjean P., Roques B. NMR structure of the HIV-1 regulatory protein Vpr. J Mol Biol 2003, 327:215-227.
20. Planelles V., Benichou S. Vpr and its interactions with cellular proteins. HIV interactions with host cell proteins. Curr Top Microbiol Immunol 2009, 177-200.
21. Nie Z., Bergeron D., Subbramanian R.A., Yao X.J., Checroune F., Rougeau N., et al. The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells. J Virol 1998, 72:4104-4115.
22. Yao X.J., Subbramanian R.A., Rougeau N., Boisvert F., Bergeron D., Cohen E.A. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995, 69:7032-7044.
23. Singh S.P., Tomkowicz B., Lai D., Cartas M., Mahalingam S., Kalyanaraman V.S., et al. Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol 2000, 74:10650-10657.
24. Kogan M., Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011, 8:25.
25. Thotala D., Schafer E.A., Majumder B., Janket M.L., Wagner M., Srinivasan A., et al. Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 2004, 328:89-100.
26. Sherman M.P., de Noronha C.M.C., Pearce D., Greene W.C. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G2 cell cycle arrest. J Virol 2000, 74:8159-8165.
27. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008, 130:10876-10877.
28. Liao K.H.K., Lin Y.S., Macosko C.W., Haynes C.L. Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts. ACS Appl Mater Inter 2011, 3:2607-2615.
29. Zhang M., Yin B.C., Wang X.F., Ye B.C. Interaction of peptides with graphene oxide and its application for real-time monitoring of protease activity. Chem Commun 2011, 47:2399-2401.
30. Zhang Y., Zhang J., Huang X., Zhou X., Wu H., Guo S. Assembly of graphene oxide-enzyme conjugates through hydrophobic interaction. Small 2012, 8:154-159.
31. Lu C.H., Li J., Zhang X.L., Zheng A.X., Yang H.H., Chen X., et al. A general approach for monitoring peptide-protein interactions based on graphene-peptide complex. Anal Chem 2011, 83:7276-7282.
32. Kim S.N., Kuang Z.F., Slocik J.M., Jones S.E., Cui Y., Farmer B.L., et al. Preferential binding of peptides to graphene edges and planes. J Am Chem Soc 2011, 133:14480-14483.
33. Cui Y., Kim S.N., Jones S.E., Wissler L.L., Naik R.R., McAlpine M.C. Chemical functionalization of graphene enabled by phage displayed peptides. Nano Lett 2010, 10:4559-4565.
34. Katoch J., Kim S.N., Kuang Z.F., Farmer B.L., Nalk R.R., Tatulian S.A., et al. Structure of a peptide adsorbed on graphene and graphite. Nano Lett 2012, 12:2342-2346.
35. Poh H.L., Sanek F., Ambrosi A., Zhao G.J., Sofer Z., Pumera M. Graphenes prepared by Staudenmaier, Hofmann and Hummers methods with consequent thermal exfoliation exhibit very different electrochemical properties. Nanoscale 2012, 4:3515-3522.
36. Liu L., Zhang L., Mao X.B., Niu L., Yang Y.L., Wang C. Chaperon-mediated single molecular approach toward modulating A beta peptide aggregation. Nano Lett 2009, 9:4066-4072.
37. Mao X.B., Wang C.X., Wu X.K., Ma X.J., Liu L., Zhang L., et al. Beta structure motifs of islet amyloid polypeptides identified through surface-mediated assemblies. Proc Natl Acad Sci U S A 2011, 108:19605-19610.
38. Elgersma R.C., Mulder G.E., Kruijtzer J.A.W., Posthuma G., Rijkers D.T.S., Liskamp R.M.J. Transformation of the amyloidogenic peptide amylin (20-29) into its corresponding peptoid and retropeptoid: access to both an amyloid inhibitor and template for self-assembled supramolecular tapes. Bioorg Med Chem Lett 2007, 17:1837-1842.
39. Ma X.J., Liu L., Mao X.B., Niu L., Deng K., Wu W.H., et al. Amyloid beta (1-42) folding multiplicity and single-molecule binding behavior studied with STM. J Mol Biol 2009, 388:894-901.
40. Mao X.B., Ma X.J., Liu L., Niu L., Yang Y.L., Wang C. Structural characteristics of the beta-sheet-like human and rat islet amyloid polypeptides as determined by scanning tunneling microscopy. J Struct Biol 2009, 167:209-215.
41. Kawasaki T., Asaoka K., Mihara H., Okahata Y. Nonfibrous β-structured aggregation of an Aβ model peptide (Ad-2α) on GM1/DPPC mixed monolayer. Surf J Colloid Inter Sci 2006, 294:295-303.
42. Li C., Adamcik J., Mezzenga R. Biodegradable nanocomposites of amyloid fibrils and graphene with shape-memory and enzyme-sensing properties. Nat Nanotechnol 2012, 7:421-427.
43. Pronchik J., He X., Giurleo J.T., Talaga D.S. In vitro formation of amyloid from α-Synuclein is dominated by reactions at hydrophobic interfaces. J Am Chem Soc 2010, 132:9797-9803.
44. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
45. Zhang X., Yin J., Peng C., Hu W., Zhu Z., Li W., et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 2011, 49:986-995.
46. Wang K., Ruan J., Song H., Zhang J., Wo Y., Guo S., et al. Biocompatibility of graphene oxide. Nanoscale Res Lett 2011, 6:8-15.
47. Chang Y., Yang S.T., Liu J.H., Dong E., Wang Y., Cao A., et al. In vitro toxicity evaluation of graphene oxide on A549 cells. Toxicol Lett 2011, 200:201-210.
48. Ruiz O.N., Fernando K.A.S., Wang B., Brown N.A., Luo P.G., McNamara N.D., et al. Graphene oxide: a nonspecific enhancer of cellular growth. ACS Nano 2011, 5:8100-8107.
49. Chen H., Müller M.B., Gilmore K.J., Wallace G.G., Li D. Mechanically strong, electrically conductive, and biocompatible graphene paper. Adv Mater 2008, 20:3557-3561.
50. Agarwal S., Zhou X., Ye F., He Q., Chen G.C.K., Soo J., et al. Interfacing live cells with nanocarbon substrates. Langmuir 2010, 26:2244-2247.
51. Park S., Mohanty N., Suk J.W., Nagaraja A., An J., Piner R.D., et al. Biocompatible, robust free-standing paper composed of a TWEEN/graphene composite. Adv Mater 2010, 22:1736-1740.
52. Yang K., Li Y., Tan X., Peng R., Liu Z. Behavior and toxicity of graphene and its functionalized derivatives in biological systems. Small 2012, 10.1002/smll.201201417.